Evidence map›Paper›PMID 40692869›Full record

SynthesisFrontiers in oncology2025

Prognostic and clinicopathological value of dbc1 expression in human cancers: a systematic review and meta-analysis.

Haojia Wang, Xinhong Cheng, Bruce Xianzhuo Zhang, Yong Wang, Shuo Gao, Fanghui Ding, Xiaojing Song, Dandan Li, Haixu Ni, Yang Luo and 1 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Haojia WangThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Xinhong ChengThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Bruce Xianzhuo ZhangFaculty of Health Sciences, University of Macau, Macau, Macau SAR, China.
Yong WangThe First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Shuo GaoThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Fanghui DingThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Xiaojing SongThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Dandan LiThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Haixu NiThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Yang LuoThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Xun LiThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: DBC1 is a large nuclear protein that is thought to influence the development of several human cancers. However, further research has revealed that the relationship between DBC1 and the prognosis and pathological characteristics of cancer patients is controversial. The aim of this paper is to explore the significance of DBC1 in cancer through the method of meta-analysis. Methods: A systematic search of the PubMed, Web of Science, Embase, CNKI, and Wanfang databases was conducted, resulting in the identification of 25 studies encompassing 4014 patients. The Hazard Ratio (HR) and ratio ratios (RR) were combined using STATA 14.0 software, and 95% confidence intervals (CI) were obtained to assess the association of DBC1 with prognostic and pathologic characteristics of cancer patients. Results: Meta-analysis of the combined results demonstrated that patients with cancer who exhibited DBC1 overexpression exhibited shorter overall survival (OS) (n = 17, HR = 1.948, 95%CI: [1.280-2.964], P = 0.002, Conclusion: DBC1 overexpression is associated with poor survival cycle and pathologic features in cancer patients, and it has the potential to be a predictive prognostic marker for cancer. However, more high-quality prospective studies are still needed to validate our conclusions. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023426104.

Indexed as

carcinomaclinicopathological characteristicsDBC1meta-analysisprognosis

Identifiers

PMID40692869
PMCPMC12278428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.